| Literature DB >> 27009367 |
Jin-Ching Lin1,2, Chen-Chi Wang3,2, Rong-San Jiang3, Wen-Yi Wang4, Shih-An Liu3,2.
Abstract
We investigated the frequency of microsatellite alteration and their impact on survival in head and neck squamous cell carcinoma patients from an endemic betel quid chewing area. We collected 116 head and neck squamous cell carcinoma specimens along with corresponding surgical margins which were confirmed by pathological examination. Ten oligonucleotide markers were chosen for the assessment of microsatellite alteration. The specimens were amplified by polymerase chain reaction followed by automatic fragment analysis. There were 44 specimens (37.9%) with microsatellite instability (MSI) in at least one marker while more than half of the specimens (n = 68, 58.6%) had loss of heterozygosity (LOH) in at least one marker. Though MSI/LOH was not correlated with the survival of head and neck squamous cell carcinoma patients, presence of MSI in the tumor-free surgical margins was associated with local recurrence (odds ratio: 15.14; 95% confidence interval: 6.451 ~ 35.53; P < 0.001). Genomic assessment of surgical margin can help surgeons to identify head and neck squamous cell carcinoma patients who are at risk of developing local recurrence in a betel quid-prevalent region.Entities:
Mesh:
Year: 2016 PMID: 27009367 PMCID: PMC4806345 DOI: 10.1038/srep22614
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Descriptive and bivariate analysis of head and neck squamous cell carcinoma patients with or without microsatellite instability (MSI).
| Variables | Total no. of patients (% in column) | No. of patients (%) | ||
|---|---|---|---|---|
| MSI (n = 44) | Without MSI (n = 72) | |||
| Age (yr) | 50.5 +/- 10.1 | 54.0 +/- 12.0 | 0.108 | |
| BMI (Kg/M2) | 24.2 +/- 3.9 | 25.2 +/- 4.5 | 0.206 | |
| F/U duration (month) | 22.0 +/- 9.6 | 22.0 +/- 11.3 | 0.988 | |
| Gender (Female/Male) | 7/109 | 3/41 | 4/68 | 0.999 |
| Smoking | 0.851 | |||
| Yes | 92(79.3%) | 34(37.0%) | 58(63.0%) | |
| No | 24(20.7%) | 10(41.7%) | 14(58.3%) | |
| Alcohol | 0.208 | |||
| Heavy | 37(31.9%) | 16(43.2%) | 21(56.8%) | |
| Social | 47(40.5%) | 20(42.6%) | 27(57.4%) | |
| No | 32(27.6%) | 8(25.0%) | 24(75.0%) | |
| Betel quid | 0.392 | |||
| Yes | 83(71.6%) | 34(41.0%) | 49(59.0%) | |
| No | 33(28.4%) | 10(30.3%) | 23(69.7%) | |
| Primary tumor sites | 0.999 | |||
| Oral cavity | 104(89.7%) | 40(38.5%) | 64(61.5%) | |
| Others | 12(10.3%) | 4(33.3%) | 8(66.7%) | |
| Histological features | 0.736 | |||
| Well differentiated | 8(6.9%) | 2(25.0%) | 6(75.0%) | |
| Moderately differentiated | 82(70.7%) | 32(39.0%) | 50(61.0%) | |
| Poorly or undifferentiated | 26(22.4%) | 10(38.5%) | 16(61.5%) | |
| Perineural invasion | 0.452 | |||
| Yes | 26(22.4%) | 12(46.2%) | 14(53.8%) | |
| No | 90(77.6%) | 32(35.6%) | 58(64.4%) | |
| Angiolymphatic invasion | 0.532 | |||
| Yes | 26(22.4%) | 8(30.8%) | 18(69.2%) | |
| No | 90(77.6%) | 36(40.0%) | 54(60.0%) | |
| Extracapsular invasion | 0.202 | |||
| Yes | 11(9.5%) | 2(18.2%) | 9(81.8%) | |
| No | 105(90.5%) | 42(40.0%) | 63(60.0%) | |
| Pathological stage | 0.853 | |||
| Stage I-II | 54(46.6%) | 20(37.0%) | 34(63.0%) | |
| Stage III-IV | 62(53.4%) | 24(38.7%) | 38(61.3%) | |
| Postoperative radiotherapy | 0.968 | |||
| Yes | 53(45.7%) | 20(37.7%) | 33(62.3%) | |
| No | 63(54.3%) | 24(38.1%) | 39(61.9%) | |
| Local recurrence | 0.058 | |||
| Yes | 26(22.4%) | 14(53.8%) | 12(46.2%) | |
| No | 90(77.6%) | 30(33.3%) | 60(66.7%) | |
| Survival status | 0.059 | |||
| Alive | 101(87.1%) | 35(34.7%) | 66(65.3%) | |
| Death | 15(12.9%) | 9(60.0%) | 6(40.0%) | |
†Fisher’s exact test.
Descriptive and bivariate analysis of head and neck squamous cell carcinoma patients with or without loss of heterozygosity (LOH).
| Variables | Total no. of patients (% in column) | No. of patients (%) | ||
|---|---|---|---|---|
| LOH (n = 68) | Without LOH (n = 48) | |||
| Age (yr) | 51.4 +/- 11.0 | 54.4 +/- 11.9 | 0.162 | |
| BMI (Kg/M2) | 25.3 +/- 4.4 | 24.1 +/- 4.0 | 0.138 | |
| F/U duration (month) | 22.6 +/- 10.3 | 21.1 +/- 11.1 | 0.455 | |
| Gender (Female/Male) | 7/109 | 2/66 | 5/43 | 0.124 |
| Smoking | 0.974 | |||
| Yes | 92(79.3%) | 54(58.7%) | 38(41.3%) | |
| No | 24(20.7%) | 14(58.3%) | 10(41.7%) | |
| Alcohol | 0.196 | |||
| Heavy | 37(31.9%) | 26(70.3%) | 11(29.7%) | |
| Social | 47(40.5%) | 26(55.3%) | 21(44.7%) | |
| No | 32(27.6%) | 16(50.0%) | 16(50.0%) | |
| Betel quid | 0.885 | |||
| Yes | 83(71.6%) | 49(59.0%) | 34(41.0%) | |
| No | 33(28.4%) | 19(57.6%) | 14(42.4%) | |
| Primary tumor sites | 0.550 | |||
| Oral cavity | 104(89.7%) | 62(59.6%) | 42(40.4%) | |
| Others | 12(10.3%) | 6(50.0%) | 6(50.0%) | |
| Histological features | 0.261 | |||
| Well differentiated | 8(6.9%) | 4(50.0%) | 4(50.0%) | |
| Moderately differentiated | 82(70.7%) | 52(63.4%) | 30(36.6%) | |
| Poorly or undifferentiated | 26(22.4%) | 12(46.2%) | 14(53.8%) | |
| Perineural invasion | 0.307 | |||
| Yes | 26(22.4%) | 18(69.2%) | 8(30.8%) | |
| No | 90(77.6%) | 50(55.6%) | 40(44.4%) | |
| Angiolymphatic invasion | 0.054 | |||
| Yes | 26(22.4%) | 20(76.9%) | 6(23.1%) | |
| No | 90(77.6%) | 48(53.3%) | 42(46.7%) | |
| Extracapsular invasion | 0.359 | |||
| Yes | 11(9.5%) | 8(72.7%) | 3(27.3%) | |
| No | 105(90.5%) | 60(57.1%) | 45(42.9%) | |
| Pathological stage | 0.662 | |||
| Stage I-II | 54(46.6%) | 30(55.6%) | 24(44.4%) | |
| Stage III-IV | 62(53.4%) | 38(61.3%) | 24(38.7%) | |
| Postoperative radiotherapy | 0.870 | |||
| Yes | 53(45.7%) | 32(60.4%) | 21(39.6%) | |
| No | 63(54.3%) | 36(57.1%) | 27(42.9%) | |
| Local recurrence | 0.307 | |||
| Yes | 26(22.4%) | 18(69.2%) | 8(30.8%) | |
| No | 90(77.6%) | 50(55.6%) | 40(44.4%) | |
| Survival status | 0.338 | |||
| Alive | 101(87.1%) | 57(56.4%) | 44(43.6%) | |
| Death | 15(12.9%) | 11(73.3%) | 4(26.7%) | |
†Fisher’s exact test.
Figure 1Disease-specific survival curves of head and neck squamous cell carcinoma patients based on the status of microsatellite alteration.
(MSI: microsatellite instability; LOH: loss of heterozygosity).
Cox proportional hazard model.
| Variables | No. of patients (N = 116) | Relative Risk | 95% Confidence Interval | ||
|---|---|---|---|---|---|
| Lower limit | Upper limit | ||||
| Age | |||||
| <50 years | 49 | 1.000 | |||
| >=50 years | 67 | 1.306 | 0.624 | 0.450 | 3.790 |
| Gender | |||||
| Female | 7 | 1.000 | |||
| Male | 109 | 0.412 | 0.407 | 0.050 | 3.357 |
| Primary tumor site | |||||
| Oral cavity | 104 | 1.000 | |||
| Others | 12 | 0.573 | 0.594 | 0.074 | 4.445 |
| MSI | |||||
| No | 72 | 1.000 | |||
| Yes | 44 | 2.242 | 0.168 | 0.711 | 7.075 |
| LOH | |||||
| No | 48 | 1.000 | |||
| Yes | 68 | 1.115 | 0.865 | 0.317 | 3.921 |
| Pathological stage | |||||
| I-II | 54 | 1.000 | |||
| III-IV | 62 | 4.496 | 0.022 | 1.237 | 16.34 |
*Reference group.
Abbreviation: MSI, microsatellite instability; LOH: loss of heterozygosity.
Factors associated with local recurrence based on logistic regression model.
| Variables | No. of margins (N = 351) | Odds Ratio | 95% Confidence Interval | ||
|---|---|---|---|---|---|
| Lower limit | Upper limit | ||||
| Age | |||||
| <= 50 years | 161 | 1.111 | 0.803 | 0.484 | 2.550 |
| > 50 years | 190 | 1.000 | |||
| Gender | |||||
| Female | 12 | 2.012 | 0.421 | 0.367 | 11.03 |
| Male | 339 | 1.000 | |||
| Pathological stage | |||||
| Stage III, IV | 191 | 2.520 | 0.044 | 1.026 | 6.186 |
| Stage I, II | 160 | 1.000 | |||
| Primary tumor site | 0.105 | ||||
| Hypopharynx | 13 | 4.002 | 0.061 | 0.940 | 17.04 |
| Oropharynx | 23 | 0.385 | 0.388 | 0.044 | 3.357 |
| Oral cavity | 315 | 1.000 | |||
| MSI | |||||
| Yes | 40 | 15.14 | <0.001 | 6.451 | 35.53 |
| No | 311 | 1.000 | |||
| LOH | |||||
| Yes | 74 | 1.295 | 0.577 | 0.522 | 3.216 |
| No | 277 | 1.000 | |||
*Reference group.
Abbreviation: MSI: microsatellite instability; LOH: loss of heterozygosity.
Figure 2Representative sample of microsatellite instability (MSI) in selected microsatellite markers.